The fate of Xoma Royalty’s proposed acquisition of LAVA Therapeutics hangs in the balance as shareholders convene for a decisive vote. The biotechnology firm’s pursuit of its competitor has reached its final stages, with revised terms significantly altering the transaction’s financial dynamics and sending technical signals about Xoma’s stock performance.
Revised Terms Shape Final Negotiations
During today’s extraordinary general meeting in Amsterdam, LAVA Therapeutics shareholders are determining whether to accept Xoma Royalty’s takeover offer under substantially modified conditions. The per-share cash consideration has been reduced from the original range of $1.16 to $1.24 down to just $1.04. This downward adjustment is partially offset by the introduction of a contingent value right that could yield up to $0.23 per share post-transaction, though this additional payment remains dependent on the resolution of certain liabilities.
Concurrently, Xoma has lowered the minimum cash condition required to complete the deal from $31.5 million to $24.5 million. These strategic concessions appear designed to increase the likelihood of transaction approval while shifting financial burden toward LAVA’s investor base.
Technical Indicators Flash Bullish Signals
As acquisition negotiations reach their climax, Xoma’s shares are demonstrating encouraging technical patterns. The stock successfully breached its 200-day moving average on Thursday, an event many market participants interpret as a bullish development. This breakthrough represents the clearing of a significant technical hurdle, though the 50-day moving average continues to present resistance.
Currently trading at €29.60, Xoma’s equity has appreciated 15.6% since the beginning of the year. Despite this advance, the shares remain 12% below their 52-week peak of €33.80, suggesting the acquisition outcome could provide the necessary catalyst for further gains.
Should investors sell immediately? Or is it worth buying Xoma?
Advertisement:
Is your stock positioned for a breakout? Our complimentary report outlines the five most critical candlestick formations that help identify early breakout signals, including moves above key moving averages. Request Your Free Candlestick Pattern Guide
Timeline and Conditions for Completion
The tender offer for LAVA shares remains open until November 12. For the acquisition to proceed, two critical conditions must be satisfied: at least 80% of LAVA shares must be tendered, and today’s shareholder vote in Amsterdam must yield a favorable outcome. Assuming both requirements are met, transaction closure could occur before year-end during the fourth quarter.
The central question facing investors is whether Xoma’s aggressive negotiation stance will ultimately prove advantageous or potentially jeopardize the entire acquisition. The coming days will reveal whether the company’s hardline approach delivers value or undermines its strategic objectives.
Ad
Xoma Stock: Buy or Sell?! New Xoma Analysis from November 7 delivers the answer:
The latest Xoma figures speak for themselves: Urgent action needed for Xoma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 7.
Xoma: Buy or sell? Read more here...
